These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21490308)

  • 1. Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review.
    Peura PK; Martikainen JA; Purmonen TT; Turunen JH
    Med Decis Making; 2012; 32(2):237-45. PubMed ID: 21490308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
    Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
    Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
    Jang S; Chae YK; Haddad T; Majhail NS
    Breast Cancer Res Treat; 2010 Jun; 121(2):273-9. PubMed ID: 20352486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflict of interest in industry-sponsored economic evaluations: real or imagined?
    Barbieri M; Drummond MF
    Curr Oncol Rep; 2001 Sep; 3(5):410-3. PubMed ID: 11489241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
    Bero L; Oostvogel F; Bacchetti P; Lee K
    PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of economic impact of targeted oral anticancer medications.
    Shen C; Chien CR; Geynisman DM; Smieliauskas F; Shih YC
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):45-69. PubMed ID: 24378038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial relationships in economic analyses of targeted therapies in oncology.
    Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
    J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
    Friedberg M; Saffran B; Stinson TJ; Nelson W; Bennett CL
    JAMA; 1999 Oct; 282(15):1453-7. PubMed ID: 10535436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
    Golder S; Loke YK
    Br J Clin Pharmacol; 2008 Dec; 66(6):767-73. PubMed ID: 18754841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are pharmaceuticals cost-effective? A review of the evidence.
    Neumann PJ; Sandberg EA; Bell CM; Stone PW; Chapman RH
    Health Aff (Millwood); 2000; 19(2):92-109. PubMed ID: 10718025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
    Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
    Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of triptan products for migraine.
    Perfetto EM; Weis KA; Mullins CD; Subedi P; Healey PJ
    Value Health; 2005; 8(6):647-55. PubMed ID: 16283865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis.
    Krauth D; Anglemyer A; Philipps R; Bero L
    PLoS Biol; 2014 Jan; 12(1):e1001770. PubMed ID: 24465178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis.
    Anglemyer AT; Krauth D; Bero L
    BMC Med Res Methodol; 2015 Mar; 15():12. PubMed ID: 25880564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins.
    Alasbali T; Smith M; Geffen N; Trope GE; Flanagan JG; Jin Y; Buys YM
    Am J Ophthalmol; 2009 Jan; 147(1):33-38.e2. PubMed ID: 18760766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of sponsorship bias in economic studies of antidepressants.
    Baker CB; Johnsrud MT; Crismon ML; Rosenheck RA; Woods SW
    Br J Psychiatry; 2003 Dec; 183():498-506. PubMed ID: 14645020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of industry sponsorship on the acceptance of abstracts and their publication.
    McLennan M; Leong FC; Steele A; Harris J
    Am J Obstet Gynecol; 2008 May; 198(5):579.e1-4. PubMed ID: 18455539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.